Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EST-001
- Development stage
- Preclinical
- Lead developer
- Estrenue
- Modality
- Small Molecules
- Administration
- Intradermal, Topical
01
Overview
EST-001 is a clinical-stage topical formulation of estradiol developed by Estrenue for the treatment of facial skin aging. It utilizes Estrenue's proprietary Foroderm platform, which consists of elongated silicon-based microparticles applied via a microtextured applicator to deliver the active hormone directly into the viable epidermis. This localized delivery system is designed to produce targeted hormonal effects in facial skin while minimizing systemic exposure, maintaining serum estradiol levels within the post-menopausal range. EST-001 is being developed under the FDA's 505(b)(2) regulatory pathway, bridging to the established safety and pharmacokinetic profiles of approved topical estradiol products.
02
Targets
ESR1 (ERα)ESR2 (ERβ)GPER1 (G protein-coupled estrogen receptor 1)
Beyond the preview
Go deeper on EST-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EST-001.